Thus, targeting Tregs in tumor bearing hosts represents a strategy for tumor immunotherapy (4–6) although studies in some human tumor tissues have suggested FOXP3 effects only as a contributory, but not a deterministic role, on tumor malignant growth (7). Here, FOXP3 is linked to neoplasm.